The backing behind every claim

Every number cited.
Every structure explained.

Seven deep-dives covering the clinical science, the demand pools, the billing architecture, and the compliance posture. Open any article to read the full evidence base behind the claim.

The science

tPEMF: what it is, how it works, and why 17 years of trials hold up

Targeted Pulsed Electromagnetic Field therapy modulates intracellular calcium signaling through the calmodulin pathway, producing a downstream anti-inflammatory and tissue-repair cascade.

Read the evidence →

Demand pool #1

Post-surgical recovery: why 47,000 deaths a year is a distribution problem

Post-surgical pain is the primary on-ramp to opioid dependence in the U.

Read the evidence →

Demand pool #2

Chronic MSK pain: 32.5 million Americans who've run out of standard options

Osteoarthritis affects 32.

Read the evidence →

Demand pool #3

G0329 has existed since 2004. Most eligible patients still don't know.

HCPCS code G0329 (electromagnetic therapy for chronic wounds) has been a Medicare benefit since 2004.

Read the evidence →

The surgeon incentive

Remote Therapeutic Monitoring: $115 per patient per cycle. Surgeon's own NPI. Auto-documented.

Remote Therapeutic Monitoring (CPT 98975 + 98977 + 98980) pays approximately $115.

Read the evidence →

Compliance architecture

Anti-Kickback compliance: why this deal is clean, and how to verify it

The Anti-Kickback Statute (42 USC 1320a-7b(b)) prohibits remuneration to induce referrals for federally covered items.

Read the evidence →

The prescription path

HSA/FSA + LMN: turning a $500 sticker into a $357 purchase with no paperwork

FDA Class II devices require a physician's prescription.

Read the evidence →

The first result

57% less pain — inside the first hour after surgery

In a double-blind, placebo-controlled RCT published in Plastic & Reconstructive Surgery, patients using the active tPEMF device reported pain scores roughly 57% lower than the sham group at one hour.

Read the evidence →

The drug-free outcome

2.2× less narcotic use — from a blinded, randomized trial

In Rhode et al.

Read the evidence →

Cardiac surgery

70% less morphine after bypass — in patients who need it most

Work from Baylor College of Medicine and the DeBakey VA examined tPEMF in coronary artery bypass (CABG) patients and found roughly a 70% reduction in morphine-equivalent dose.

Read the evidence →

The economic proof

2 fewer days in the hospital — the number that moves budgets

Alongside the 70% morphine reduction, the CABG study found approximately a two-day shorter median hospital length of stay.

Read the evidence →

The double-blind result

87% less pain after augmentation — from a 42-patient double-blind trial

Heden and Pilla (Aesthetic Plastic Surgery, 2008) ran a 42-patient double-blind trial of tPEMF following breast augmentation and found an 87% reduction in post-operative pain (p < 0.

Read the evidence →

The safety record

Zero adverse events — across millions of treatments

No serious adverse events attributable to tPEMF have been documented across millions of treatments and the full published clinical record.

Read the evidence →

Knee replacement

50% less post-operative pain after total knee replacement

A 2023 peer-reviewed orthopedic RCT found approximately 50% reduction in post-operative pain in tPEMF-treated patients following total knee arthroplasty.

Read the evidence →

Osteoarthritis

60% sustained pain reduction in osteoarthritis — maintained over time

SofPulse clinical monitoring data show a 60% reduction in OA pain maintained over the observation period.

Read the evidence →
← Back to the walkthrough